CD30.CAR-T

DRUG2 trials

Sponsors

Tessa Therapeutics

Conditions

Anaplastic Large Cell LymphomaDiffuse Large B Cell LymphomaExtranodal NK/T-cell LymphomaHodgkin Disease RecurrentHodgkin Disease RefractoryHodgkin Disease, PediatricHodgkin Lymphoma, AdultPeripheral T Cell Lymphoma

Phase 1

Phase 1 Study of Autologous CD30.CAR-T in Relapsed or Refractory CD30 Positive Non-Hodgkin Lymphoma

Active, not recruitingNCT04526834

Tessa TherapeuticsAnaplastic Large Cell Lymphoma, Diffuse Large B Cell Lymphoma, Extranodal NK/T-cell Lymphoma +2

Start: 2021-09-08End: 2036-03-31Target: 21Updated: 2023-04-20

Phase 2

Phase 2 Study Evaluating Autologous CD30.CAR-T Cells in Patients With Relapsed/Refractory Hodgkin Lymphoma (CHARIOT)

Active, not recruitingNCT04268706

Tessa TherapeuticsHodgkin Disease, Pediatric, Hodgkin Disease Recurrent, Hodgkin Disease Refractory +1

Start: 2021-02-01End: 2037-03-31Target: 97Updated: 2023-04-05

Related Papers

Ultrasensitive Circulating Tumor DNA (ctDNA) Dynamics after Autologous CD30.CAR-T Cell Therapy for Relapsed or Refractory (r/r) Classical Hodgkin Lymphoma (CHARIOT Trial)

Blood2022-11-15